Tag: 200-300

Srinivas, Avula; Rao, Enugala Kalyan published an article in 2021, the title of the article was Synthesis and anticancer activity of triazole linked macrocycles and heterocycles.Category: esters-buliding-blocks And the article contains the following content:

Synthesis of macrocylic enones starting from alkyl ether and triazole as a linker was achieved using click reaction and intramol. aldol condensation. The newly synthesized macrocyclic enone was successfully utilized as a dipolarophile in 1,3-dipolar cycloaddition The dipoles generated from hydrazine hydrochloride, hydroxylamine and guanidine hydrochloride were reacted with macrocyclic enone to give a new class of spiro aminopyrimidines, Ph pyrazoles and isoxazoles grafted macrocycles in good yield. The structures of newly synthesized compounds were confirmed with IR, NMR and mass spectroscopy and evaluated for their anti cancer activity. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Category: esters-buliding-blocks

The Article related to triazole linked macrocycle spiro aminopyrimidine phenyl pyrazole isoxazole anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 15, 2010, Wu, Yusheng; Zou, Dapeng; Li, Jingya; Guo, Ruiyun; Qin, Lijin; Cui, Hongmeng; Cui, Xiuling published a patent.COA of Formula: C12H14F3NO2 The title of the patent was Catalysis system for preparation of N-Boc arylamines. And the patent contained the following:

The catalysis system consists of Pd acetate, phosphine ligand XPhos and Cs carbonate at a mol. ratio 1:3:45-50. The preparation comprises adding Pd acetate, phosphine ligand XPhos, Cs carbonate, tertbutyl amino formate, aryl halide, and anhydrous dioxane at a mol. ratio 0.03:0.09:1.35-1.50:1.2:1:90-95 in a dry reactor, stirring, reacting at 100°C for 1.5-24 h in inert gas (nitrogen) protection, adding water after finishing reaction, extracting with Et acetate, combining organic phases, drying the combined organic phases, concentrating, and purifying. The aryl halide is aryl chloride, aryl bromide, heterogeneous aryl chloride or heterogeneous aryl bromide. The catalysis system can be used for preparation of N-Boc-arylamine compounds The invention has the advantages of mild condition, easy operation, simple post treatment, high yield, less environment pollution, etc.. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).COA of Formula: C12H14F3NO2

The Article related to arylamine butoxycarbonyl preparation aryl halide carbamate coupling catalyst palladium, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.COA of Formula: C12H14F3NO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 17, 2020, Qian, Shengyou; Pu, Xingwen; Chang, Guanjun; Huang, Ying; Yang, Yudong published an article.SDS of cas: 141940-37-6 The title of the article was Rh(III)-catalyzed oxidative C-H activation/domino annulation of anilines with 1,3-diynes: a rapid access to blue-emitting tricyclic N,O-heteroaromatics. And the article contained the following:

Disclosed herein is a rhodium-catalyzed oxidative C-H activation/domino annulation of N-Boc-anilines with 1,3-diynes for the construction of tricyclic N,O-heteroaromatics This reaction features easily available substrates, mild reaction conditions, high regioselectivity, mono/diannulation selectivity, and intra/intermol. annulation selectivity. Moreover, this synthetic protocol enables the rapid assembly of a library of blue-emitting mols. with high quantum yields, among of which two fluorophores with pure blue-emission in toluene are discovered. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).SDS of cas: 141940-37-6

The Article related to rhodium catalysis oxidative anilines diyne tricyclic blue emitting heteroaromatic, Dyes, Organic Pigments, Fluorescent Brighteners, and Photographic Sensitizers: Other Dyes and Pigments and other aspects.SDS of cas: 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 29, 1998, Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C. published a patent.Safety of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate The title of the patent was Preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists. And the patent contained the following:

XYZAB [I; A = (un)substituted (hetero)arylene; B = O(CH2)mCO2R9, (CH2)nCO2R9, CHR8(CH2)pCO2R9, OCHR8(CH2)pCO2R9; R8 = H, OH, alkyl, alkoxy, aryl, etc.; R9 = H, (ar)alkyl, aryl, acylalkyl, etc.; X = (un)substituted heterocyclyl or -heteroaryl; Y = (un)substituted heterocyclylene or -(hetero)arylene; Z = bond, NH, CONH, CO, CH2CH2, etc.; m = 1-3; n,p = 0-3] were prepared Thus, 4-(H2N)C6H4CO2Me was cyclocondensed with HN(CH2CH2Cl)2 and the N-protected and saponified product amidated by 4-BrC6H4NH2 to give the bromobenzanilide which was condensed with CH2:CHCO2Me and the product converted in 3 addnl. steps to 4-RC6H4CONHC6H4(CH2CH2CO2H)-4 (R = piperazino). Data for biol. activity of I were given. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).Safety of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate

The Article related to piperazinobeznoylaminophenylalkanoate preparation fibrinogen receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 30, 2011, Badiger, Sangamesh; Behnke, Dirk; Betschart, Claudia; Chaudhari, Vinod; Cotesta, Simona; Hinrichs, Juergen Hans-Hermann; Ofner, Silvio; Pandit, Chetan published a patent.Quality Control of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate The title of the patent was Preparation of diaza-spiro[5.5]undecanes as orexin receptor antagonists. And the patent contained the following:

The title compounds I [A = (un)substituted 8-10 membered fused bicyclic aromatic ring system which may contain from 1-4 heteroatoms selected from N, O and S, wherein the ring system may contain not more than 2 O atoms and not more than 2 S atoms; or A = (un)substituted 5-6 membered monocyclic aromatic ring system which may contain 1-4 heteroatoms selected from N, O and S, wherein the ring system may contain not more than 2 O atoms and not more than 2 S atoms; m = 0-6; n = 0-6; R1, R2 = halo, alkyl, haloalkyl, etc.; X1 = C(O) and X2 = N(LB); or X1 = N(LB) and X2 = C(O); L = C(R7)2; R7 = H, alkyl, haloalkyl, etc.; B = (un)substituted 5-10 membered monocyclic or fused polycyclic aromatic ring system which may contain from 1-4 heteroatoms selected from N, O and S, wherein the ring system may contain not more than 2 O atoms and not more than 2 S atoms], were prepared E.g., a multi-step synthesis of II, starting from indole-3-carboxaldehyde, was described. Exemplified compounds I were tested for inhibition of orexin-1 and orexin-2 receptors binding (data provided). Pharmaceutical compositions comprising the compound I, alone or in combination with other therapeutic agent, were also disclosed. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Quality Control of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

The Article related to diazaspiroundecane preparation orexin receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 21, 2020, Chen, Xiangyang; Pang, Yucheng published a patent.Synthetic Route of 29704-38-9 The title of the patent was Pyridazine-3-carboxamide compound, its preparation and application in medicine. And the patent contained the following:

The invention relates to pyridazine-3-carboxamide compound of formula I as Janus Kinase inhibitor, its preparation and application for treatment of Janus Kinase-mediated diseases. Compounds I, wherein Z is N or CR1; ring A is substituted C6-10 aromatic ring or 5-10-membered aromatic hetero-ring; L is a bond or substituted C1-6 alkylene; R is H, halogen, cyano, SF5, etc.; R1 is H, halo, CN, etc.; Ra, Rb, Rc , Rd and Re are independently H, halo, CN, etc.; their pharmaceutically acceptable salts, prodrug, isomers or mixtures, are claimed. The inventive compound is capable of inhibiting or controlling Janus kinase, especially tyrosine kinase 2, and can be applied to the prevention and treatment of Janus kinase-mediated diseases, especially autoimmune disease, inflammatory disease and cancer. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Synthetic Route of 29704-38-9

The Article related to pyridazine carboxamide preparation janus kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 17, 2022, Chen, Xiangyang; Pang, Yucheng published a patent.Electric Literature of 29704-38-9 The title of the patent was Pyridazine-3-carboxamide compound, its preparation and application in medicine. And the patent contained the following:

Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof. In particular, disclosed in the present invention are a compound as represented by general formula I and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing Janus kinase-mediated related diseases, in particular autoimmune diseases, inflammatory diseases and cancers, by means of using the compound or the pharmaceutically acceptable salt thereof, and a method for preparing the compound or the pharmaceutically acceptable salt thereof. Each substituent of general formula I has the same definition as that in the description. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Electric Literature of 29704-38-9

The Article related to pyridazine carboxamide preparation janus kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 16, 2009, Metzger, Axel; Qin, Lan-Ying; Cole, Andrew G.; Saionz, Kurt W.; Brescia, Marc-Raleigh; Gstach, Hubert; Wareing, James R.; Zimmermann, Juerg; Brill, Wolfgang K.-D.; Baldwin, John J.; Dolle, Roland E.; Henderson, Ian published an article.Product Details of 53838-27-0 The title of the article was Combined solution-phase and solid-phase synthesis of 2-amino-7,8-dihydropteridin-6(5H)-ones. And the article contained the following:

An efficient and general synthesis of substituted 2-amino-7,8-dihydropteridin-6(5H)-ones I [R1 = i-Bu, MeOCH2CH2, Ph, 3,4-Cl2C6H3, PhCH2CH2; R2 = Me, HOCH2, HO2CCH2CH2, H2N(CH2)4, 4-HOC6H4CH2; R3 = Ph, 4-ClC6H4, 3-pyridyl, etc.] using a combination of solution-phase and solid-phase chem. is described. Solution-phase chem. was used to produce two pyrimidine regioisomers that were separated by flash column chromatog. Utilizing the desired regioisomer II, solid-phase chem. was used to effect the rapid construction of the substituted 2-amino-7,8-dihydropteridin-6(5H)-one system in high overall yield and purity. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to pteridinone amino dihydro solution solid phase synthesis, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 1, 2011, Noguchi, Toshiya; Ushiyama, Fumihito; Horikiri, Hiromasa; Yamamoto, Keiko; Ono, Naoya; Takayama, Tetsuo; Kamiyama, Tomoko published a patent.Product Details of 1198284-94-4 The title of the patent was Preparation of heterocyclic compounds or salts thereof for use as antibacterial agents. And the patent contained the following:

Disclosed is a medicament having a strong antibacterial activity against Gram-pos. bacteria, Gram-neg. bacteria, and resistant bacteria. A compound represented by formula I [a bond containing dotted line and connecting X2 to Y1 represents single bond or double bond; Z1-6 = N, CR; R = H, (halo)alkoxy, OH, halogen, (halo)alkyl, cycloalkyl, CN, NO2, etc.; X1 = (oxo-containing) C1-4 alkylene; X2 = bonding hand, CH; Y1 = spirocyclic group; X3 = C1-4 alkylene, NR'(CH2)m, SOn, bonding hand; R’ = H, C1-6 alkyl; m, n = 0, 1, 2; R1 = C3-6 cycloalkyl, C3-6 cycloalkenyl, aryl, heterocyclic group] or a salt thereof is useful as an antibacterial agent. Thus, compound II was synthesized through a multistep process and showed antibacterial activity against Staphylococcus aureus (MIC 0.03). The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Product Details of 1198284-94-4

The Article related to heterocyclic antibacterial agent preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 1198284-94-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Yao, Shu-Feng; Cai, Zhao-Sheng; Huang, Xu-Juan; Song, Lan-Xuan published an article in 2020, the title of the article was Preparation of salicylic nitrile through direct catalytic dehydration of salicylamide with immobilized phosphoric acid as catalyst.Formula: C13H10O3 And the article contains the following content:

Salicylic nitrile was prepared through direct catalytic dehydration of salicylamide under high temperature using immobilized phosphoric acid as catalyst. The catalytic performances of different catalysts were evaluated according to the analytic results of GC-MS, and the feasibility about the preparation of salicylic nitrile by direct catalytic dehydration of salicylamide was investigated according to the composition of product determinated by GC anal. (area nomalization). Exptl. results indicated the comprehensive property of silica gel supported phosphoric acid was the best one among all of the catalysts utilized in this study. When the temperature of catalyst bed was 480 ± 10° and silica gel supported phosphoric acid was utilized as catalyst, the conversion ratio of salicylamide was 88.79%, the selectivity to salicylic nitrile was 97.97% and the yields of salicylic nitrile could up to 86.99%. Meanwhile, the exptl. results showed the increase of temperature of catalyst bed could result in the increase of the conversation of salicylamide, but much more byproduct could be formed when the temperature of catalyst bed was too high. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Formula: C13H10O3

The Article related to salicylamide immobilize phosphoric acid catalyst direct dehydration, salicylic nitrile preparation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Nitriles, Isonitriles, and Acyl Cyanides and other aspects.Formula: C13H10O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics